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Since cancer survival rates in general are increasing, second primary cancers (SPCs) account for 40 
an increasing proportion of the overall cancer burden. In some cancer registries they account for 41 
more than 20% of new diagnoses (1). Contributing factors for SPCs may be multiple, including 42 
iatrogenic adverse effects of chemotherapy or radiation, increased surveillance and the same 43 
causes that influenced patients’ first cancers, including family history and environmental causes 44 
(2-4). Chemotherapy and radiation induce DNA damage which increases the risk of SPCs, and 45 
therapy associated immunosuppression could also play a role. Treatment for MM involves 46 
intense chemotherapy and concerns about SPCs have been raised, particularly relating to the 47 
possible effects of lenalidomide and melphalan (5). The impact of family history was recently 48 
shown in survivors of Hodgkin lymphoma with an excess of lung, colorectal and breast cancers 49 
in survivors with a family history of these cancers (6). The potential importance of family history 50 
is emphasized by the fact that about 50% of patients with first primary cancer have a first-degree 51 
relative diagnosed with some cancer (7). This proportion was also high among patients 52 
diagnosed with multiple myeloma (MM), 61% (7). The other cancers in family members were 53 
diverse; including chronic lymphocytic leukemia and colorectal and prostate cancers (8, 9). 54 
 55 
In the present study we use the Swedish Family-Cancer Database, with two goals, first to assess 56 
the influence of family history on the risk of SPC, and second to estimate the influence of SPC 57 
on mortality in MM  in family members (7). A family history implies that the type of SPC (e.g., 58 
lung cancer) was the same cancer that was diagnosed in a parent or sibling (e.g. lung cancer).          59 
 60 
Methods 61 
In the Swedish Family-Cancer Database the second generation ‘offspring’ was defined as 62 
individuals born after 1931 and their patents were defined as the parental generation. Another 63 
truncation of data was caused by the start of cancer registration in Sweden in 1958. The study 64 
included 25,787 MM diagnosed from 1958 to 2015; of these 5205 were diagnosed in the 65 
offspring generation with a median age at diagnosis of 62 years. Among MM patients 360 66 
(6.9%) were diagnosed with SPC after a median follow-up time of 4 years. Among these 360, 67 
246 (68.3%) had a first-degree family history of any cancer. 68 
 69 
Relative risks (RRs) were assessed with incidence rate ratios, estimated with RRs regressed over 70 
a fixed effects generalized Poisson model. RRs for SPC were obtained by comparing incidence 71 
rates for SPC X in MM patients with rates for first cancer X in the background population of the 72 
database. Family history was defined among parents and siblings. Familial RRs were estimated 73 
by comparing incidence rates between MM patients diagnosed with cancer X as SPC and having 74 
a family history of cancer X against those diagnosed with first cancer X in the population; the 75 
reference rate was the same as above. Sex, age group, calendar-period, socio-economic status 76 
and residential areas were treated as potential confounders and were adjusted for in the 77 
regression model. Follow-up commenced from diagnosis of MM and was terminated on SPC 78 
diagnosis, emigration, death or end of follow-up period, i.e. 2015, whichever occurred first. 79 
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Confidence intervals were calculated for 5%, 1% and 0.1% level of significance (10).  All 80 
cancer-related deaths were stratified into MM, SPC and other causes, including cancers defined 81 
in death certificates and non-neoplastic causes of death. Additive and multiplicative interactions 82 
of family history and risk of SPC were tested as described (11). 83 
 84 
The study was approved by the Ethical Committee of Lund University. Analyses are performed 85 
in SAS v9.4; please contact the authors for codes. 86 
 87 
Results  88 
 89 
Among 5,205 MM patients, 360 (6.9%) were diagnosed with a SPC. Familial SPCs were 90 
compared to non-familial SPCs in Table 1, which lists all SPCs with at least two cases having the 91 
same (concordant) tumor in a parent or sibling. Ignoring the overlapping impact of more than 92 
one cancer in family, prostate cancer was the major contributor to the family history (20%) 93 
followed by colorectal (14%), breast (10%), bladder (5%), lung cancer and skin SCC (4% both). 94 
In patients without a family history of cancer, the risk of SPC was increased for skin cancer 95 
(squamous cell carcinoma, SCC, RR = 2.58) and leukemia (RR = 4.55). For patients with a 96 
family history of cancer, even though case numbers were low, risks were significantly elevated 97 
in a trend test for colorectal (RR/familial = 2.10 vs. RR/non-familial = 1.01), prostate 98 
(RR/familial   = 1.60 vs. RR/non-familial = 0.56) and skin SCC (RR/familial   = SCC, 8.82 vs. 99 
RR/non-familial = 2.58). The trend test was of borderline significance (P = 0.061) for lung 100 
cancer (RR/familial   = 5.40 vs. RR/non-familial = 1.13). The highest SPC risk was observed for 101 
MM patients with a family history of leukemia (RR = 9.14, only 2 cases). Patients with SPC with 102 
any familial cancer (N = 246) were 68.3% of all SPCs and the RR was 1.38 vs. 1.13 respectively 103 
(trend test P < 0.001). We tested interactions of significant family risks and risk of SPC and 104 
found a stronger than additive interaction for skin cancer (P = 0.04). 105 
 106 
In order to check for possible skewed patient recruitment based on the multiple applied 107 
conditions were plotted the patient accrual over the study period (Supplementary Figure 1). The 108 
diagram shows MM patients with SPC and with or without family history (246 and 114 patients) 109 
plotted by 5-year intervals of MM diagnosis. No skewing of case accrual was observed. 110 
 111 
The total number of deaths by the end of 2015 was 2872 (55.2%) among 5205 patients; and the 112 
total number of deaths among 360 patients with SPC was 228 (60.6%). The proportion was 113 
equally high among 246 patients with familial SPC, of whom 146 (59.3%) had died. 114 
Kolmogorov-Smirnov test on proportion difference found no evidence of statistical difference (P 115 
> 0.05) 116 
 117 
MM was the most common cause of death in patients without a SPC (83.4%, 2194/2629), with 118 
16.6% of deaths due to other causes (data not shown). For MM patients with a SPC, the 119 
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distribution of causes of death is shown in Table 2. MM was the leading cause with 38.7% of 120 
deaths, followed by SPC 35.8% and other causes (25.5%); among other causes the majority of 121 
deaths (62.9%) were due to non-neoplastic causes. The mortality of SPC varied between second 122 
cancer types. For second pancreatic cancer, all 7 patients died of this cancer; more than half of 123 
MM patients died of SPC when it was lung or nervous system cancer or leukemia. Other causes 124 
were important for CUP as SPC which is due to the practice of rarely describing CUP as a cause 125 
of death (12).  Among 82 deaths in patients with SPC without a cancer family history, majority 126 
was due to MM (36.6%), closely followed by SPCs (34.2%). Kolmogorov-Smirnov test found no 127 
significant difference in proportion contribution by the different causes of death in patients with 128 
or without family history (P > 0.05). 129 
 130 
 131 
Discussion 132 
 133 
The novel aspect of this study was the demonstration of the impact of familial risk on SPCs in 134 
MM patients. Accordingly, as many as 68.3% of SPCs were familial, i.e., a parent or sibling of 135 
MM patients were diagnosed with any cancer, moderately higher compared to that of 59.9% 136 
patients without an SPC. For three SPCs with significant risks, including colorectal, prostate and 137 
skin cancers, the family members had exactly the same cancer as was the SPC. It is interesting 138 
that in a recent study from this database the most consistent familial association between MM 139 
and first primary cancers included colorectal and prostate cancer and leukemia (9). This may not 140 
be coincidental and shared susceptibility may contribute to these findings. We showed also that 141 
MM patients with SPC appeared to have moderately worse prognosis (60.6% dead) compared to 142 
all MM patients (55.2% dead), while family history of SPCs did not increase mortality (59.3% 143 
dead). The limitation of the study was a relatively small sample size in spite of nation-wide 144 
coverage. The reason is that survival in MM, although improving, is still relatively poor whereby 145 
the time-window for SPCs is narrow (13). Due to the small numbers we did not undertake formal 146 
hazard ratio analysis for survival. 147 
 148 
Therapy-related SPCs in MM have mainly been associated with acute myeloid leukemia which 149 
has been increased also in a recent study on German and Swedish MM patients (5, 14). The 150 
Swedish population of that study partially overlaps with the present one were a risk (RR 4.41) of 151 
second leukemia was observed in patients lacking family history. Therapy-related side effects are 152 
still considered relatively weak in MM but the situation may changes when larger patient groups 153 
achieve long survival times (5). Family history needs to be considered a possible confounder in 154 
therapy related studies on SPCs. 155 
 156 
In conclusion, 68.3% of MM patients with SPC in had a family history of any cancer. 157 
Significantly increased associations were found for second colorectal, prostate and skin cancers 158 
and family members diagnosed with these cancers. With continued therapeutic successes in MM 159 
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treatment SPCs will be receiving increasing attention whereby the contributing role of family 160 
history deserves inquiry into its mechanistic underpinnings.  161 
 162 
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Table 1. Relative risks of SPCs among all multiple myeloma patients stratified over family 
Abbreviation: 
FDR, first degree relative; N, frequency; RR, relative risk; CI, confidence interval;  
SCC, squamous cell carcinoma; 
Bold, italics and underline indicate 5%, 1% and 0.1% level of significance; 
 
 
 
 
 
 
 
 At least 1 FDR with cancer No FDR with cancer Total Trend test 
    P value 
Cancer N RR 95% CI N RR 95% CI N RR 95% CI 
Colorectum 7 2.10 1.00 - 4.41 27 1.01 0.69 - 1.47 34 1.13 0.81 -1.58 0.033 
Lung 3 5.40 1.74 - 16.75 10 1.13 0.61 - 2.10 13 1.38 0.80 - 2.38 0.061 
Breast 4 1.13 0.42 - 3.01 24 0.93 0.62 - 1.39 28 0.95 0.66 - 1.38 0.176 
Prostate 20 1.60 1.03 - 2.48 38 0.56 0.41 - 0.77 58 0.72 0.56 - 0.93 0.006 
Melanoma 2 5.04 1.26 - 20.14 18 1.46 0.92 - 2.32 20 1.57 1.01 - 2.44 0.087 
Skin (SCC) 4 8.82 3.31 - 23.52 31 2.58 1.81 - 3.67 35 2.81 2.01 - 3.91 0.029 
Leukemia 2 9.14 2.29 - 36.55 32 4.41 3.11 - 6.24 34 4.55 3.25 - 6.37 0.093 
All 246 1.38 1.22 - 1.57 114 1.13 0.94 - 1.36 360 1.29 1.17 - 1.43 <0.001 
Table 2. Causes of death distribution of multiple myeloma patients diagnosed with SPC 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Abbreviations: 
MM multiple myeloma; SPC, second primary cancer; UAT, upper aerodigestive tract; SCC, 
squamous cell carcinoma; NHL, non-Hodgkin lymphoma; CUP, cancer of unknown primary; 
a Cases noted only when at least one death is observed due to second cancer. 
b Total includes all cancers without constraints. 
 MM a SPC Other causes 
Cancer N % N % N % 
UAT 2 50.0 2 50.0 - - 
Stomach - - 4 100.0 - - 
Colorectum 8 33.3 11 45.8 5 20.9 
Anus - - 1 100.0 - - 
Liver 2 33.3 3 50.0 1 16.7 
Pancreas - - 7 100.0 - - 
Lung 3 13.6 15 68.2 4 18.2 
Breast 6 42.9 1 7.1 7 50 
Cervix - - 1 100.0 - - 
Ovary 1 50.0 1 50.0 - - 
Prostate 11 42.3 5 19.2 10 38.4 
Kidney 3 37.5 3 37.5 2 25 
Urinary bladder 5 41.7 3 25.0 4 33.3 
Melanoma 7 58.3 3 25.0 2 16.7 
Skin (SCC) 16 72.7 1 4.5 5 22.7 
Nervous system 3 42.9 4 57.1 - - 
NHL 5 45.5 4 36.4 2 18.2 
Hodgkin lymphoma - - 1 50.0 1 50 
Leukemia 7 24.1 16 55.2 6 20.6 
CUP 3 21.4 1 7.1 10 71.4 
b Total 94 38.7 87 35.8 62 25.5 
